Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Redwood Pharma

Less than 1K followers
All
Press releases
3rd party
ShowingAll content types
Regulatory press release7/28/2024, 12:30 PM

Redwood Pharma files for bankruptcy

Redwood Pharma
Regulatory press release6/26/2024, 9:00 AM

Redwood Pharma provides a new update regarding divestment of company assets

Redwood Pharma
Press release6/12/2024, 10:00 AM

Redwood Pharma provides an update on the process for divesting the company's assets

Redwood Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release5/23/2024, 11:00 AM

Redwood Pharma provides an update on the company's future

Redwood Pharma
Press release5/8/2024, 6:30 AM

Redwood Pharma's product RP501 attracted a lot of interest at ARVO in Seattle

Redwood Pharma
Press release5/7/2024, 6:30 AM

Two international companies begin due diligence on Redwood Pharma's product RP501 ahead of potential commercial agreements

Redwood Pharma
Press release5/6/2024, 1:00 PM

Redwood Pharma's board subscribes to units in the ongoing new issue

Redwood Pharma
Press release2/28/2024, 7:30 AM

Redwood Pharma's innovative dry eye treatment to be presented at ARVO in Seattle

Redwood Pharma
Press release12/20/2023, 8:10 AM

Redwood Pharma's CEO Martin Vidaeus in year-end interview

Redwood Pharma
Press release12/19/2023, 7:00 AM

Redwood Pharma to participate in the JP Morgan Healthcare Conference

Redwood Pharma
Regulatory press release11/30/2023, 7:30 AM

Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)

Redwood Pharma
Press release11/22/2023, 7:30 AM

Redwood Pharma to participate in the NLS Days partner conference in Copenhagen

Redwood Pharma
Press release10/19/2023, 9:15 AM

Redwood Pharma to participate in the BIO-Europe partnering conference in Munich

Redwood Pharma
Regulatory press release5/31/2023, 9:10 PM

Redwood Pharma presents positive results from a clinical study with RP501 against dry eye

Redwood Pharma
Press release3/17/2023, 12:00 PM

Redwood Pharma completes recruitment for clinical trial with RP501 for dry eye

Redwood Pharma
Press release1/24/2023, 7:30 AM

Redwood Pharma takes important steps towards the commercial production of its dry eye product

Redwood Pharma
Regulatory press release12/15/2022, 4:00 PM

Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501

Redwood Pharma
Press release10/19/2022, 1:18 PM

Interview with CEO Martin Vidaeus of Redwood Pharma at BioStock Investor Meeting, Stockholm

Redwood Pharma
Press release10/14/2022, 6:30 AM

Redwood Pharma: Streamed video of CEO Martin Vidaeus presenting at Aktieportföljen Live in Stockholm, Sweden on Oct. 11, 2022

Redwood Pharma
Press release10/3/2022, 1:42 PM

Redwood Pharma to present at AKTIEPORTFÖLJEN LIVE SVERIGE in Stockholm on 11[th] of Oct. 2022 at 14:45

Redwood Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.